Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
orienx010
- Development stage
- Phase 2
- Lead developer
- OrienGene Biotechnology
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intratumoral
01
Overview
OrienX010 is an oncolytic virus therapy derived from herpes simplex virus type 1 (HSV-1), genetically engineered to express human granulocyte-macrophage colony-stimulating factor (GM-CSF). The virus has been modified by deleting or inactivating three viral genes (ICP34.5, ICP47, and ICP6) to enhance tumor selectivity and safety. Deletion of ICP34.5 allows selective replication in cancer cells while reducing neurovirulence; deletion of ICP47 enhances antigen presentation and T cell priming; inactivation of ICP6 further reduces neurotoxicity risk. The insertion of the GM-CSF gene aims to stimulate local immune responses against tumors. OrienX010 is administered via intratumoral injection and is being developed primarily for the treatment of unresectable or metastatic melanoma[1][2][4].
- Brand names
- OrienX010OrienX-010OrienX 010
- Other names
- Recombinant hGM-CSF Herpes Simplex Virus - OrienGene BiotechnologyRecombinant hGM-CSF HSV - OrienGene BiotechnologyrhGM-CSF Herpes Simplex Virus - OrienGene BiotechnologyrhGM-CSF HSV - OrienGene Biotechnology
02
Targets
NECTIN1 (Poliovirus receptor-related 1)TMEFF2
Beyond the preview
Go deeper on orienx010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on orienx010.